http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
한국형 우울장애 약물치료 알고리듬 2006 (Ⅲ) : 정신병적 양상을 동반한 주요우울삽화
김원,박원명,서정석,민경준,석정호,전덕인,전현태,이상열,송해철,홍진표,한국형 우울장애 약물치료 알고리듬 2006 연구그룹 大韓神經精神醫學會 2007 신경정신의학 Vol.46 No.6
Objectives : Since the publication of Korean Medication Algorithm Project for Major DepressiveDisorder (KMAP-MD) in 2002, there has been a substantial need for a revision due to rapid progress in the pharmacological management of depressive disorder. We revised KMAP-MD 2002 and developed the Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) 2006. Methods : We developed a questionniare for surveying the opinion of experts on pharmacotherapy of depressive disorder. The questionnaire consisted of 4 parts ; 1) treatment of non-psychotic depressive disorder, 2) treatment of psychotic de-pressive disorder, 3) treatment according to clinical subtypes and drugs choice considering adverse effects, and 4) treatment of depressive disorder in women. The questionnaire was completed by the review committee consisting of 101 experienced Korean psychiatrists. It is composed of 22 questions, and each question includes 54 sub-items. We classified the expert opinionto 3 categories (the first-line, the second-line, or the third-line) by χ²-test. Results : For depressive disorder with psychotic features, most reviewers prefer the combination of antidepressant and atypical antipsychotics. Electroconvulsive therapy and the combination of antidepressant and typical antipsychotics were the second-line treatment. Among antidepressants, venlafaxine was the most preferred, and SSRI and mirtazapine followed. Among atypical antipsychotics, quetiapine, risperidone and olanzapine were the most preferred, in this order. In patients who have no response to the first-line treatment, many reviewers recommended switching to another antidepressant or adding another atypical antipsychotics Conclusion : For severe depressive disorder with psychotic features, the combination of antidepressant and atypical antipsy-chotics was preferred for the first-line treatment. These results suggest that the medication strategies of depressive disorder are rapidly changing and reflects the recent studies and clinical experiences.
한국형 우울장애 약물치료 알고리듬 (Ⅳ) : 우울장애의 아형 및 부작용에 따른 항우울제의 선택과 여성우울장애에서의 치료전략
전현태,이상열,김원,민경준,박원명,서정석,석정호,송해철,전덕인,홍진표,한국형 우울장애 약물치료 알고리듬 2006 연구그룹 大韓神經精神醫學會 2007 신경정신의학 Vol.46 No.6
Objectives : In 2002, the Korean Medication Algorithm Project for Major depressive Disorder (KMAP-MD) was published, but there has been a need for a guideline about detailed issues of depressive disorder. We revised KMAP-MDD andreestablished Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) in 2006. Methods : A questionnaire had been developed by the executive committee for KMAP-DD. The review committee consisted of 101 experienced psychiatrists. From the total of 22 questions in the questionnaire, 7 questions were evaluated for these subjects . We classified the expert opinions to 3 categories according to its confidence interval; first, second and third line. Results : SSRI and venlafaxine were the first line antidepressants (AD) for atypical and melancholic depression. For dysthymic disorder and minor depressive disorder, SSRI was recommended as the first line medications. Only AD medications was a preferred initial strategy for treating premenstrual dysphoric disorder, mild to moderate and severe non-psychotic postpartum depression. In severe psychotic postpartum depression, combination therapy of AD and atypical antipsychotics was the treatment of choice. SSRI was preferred when considering sedation, anticholinergic and cardiovascular adverse effects. Also, experts recommended mirtazapine against gastrointestinal adverse effects and bupropion in avoiding sexual dysfunction. Conclusion : These results suggest that clinicians have to consider both clinical situations and drug adverse effects in the choice of antidepressant medications.
서정석,민경준,김원,석정호,박원명,송해철,이상열,전덕인,전현태,홍진표,한국형 우울장애 약물치료 알고리듬 2006 연구그룹 大韓神經精神醫學會 2007 신경정신의학 Vol.46 No.5
Objectives : Since the publication of Korean Medication Algorithm Project for Major depressive Disorder (KMAP-MD) in 2002, there has been a substantial need for a revision due to rapid progress in the pharmacological management for depressive disorder. We revised KMAP-MD to Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) in 2006. This paper is one of the following 4 papers consisting of Korean pharmacological algorithm for depressive disorder. Methods : The questionnaire consisted of 4 parts ; initial treatment of 1) non-psychotic depressive disorder, 2) psychotic depressive disorder, 3) treatment strategy for clinical subtypes and drug choice considering adverse effects, and 4) treatment for depressive disorder in women. It was composed of 22 questions, and each question had 54 sub-items. The questionnaire was completed by the review committee consisting of 101 experienced Korean psychiatrists. We classified the expert opinion to 3 categories (the first-line, the second-line, or the third-line). Results : For non-psychotic major depression, regardless ofthe severity of an episode, the antidepressant (AD) monotherapy was the optimal first-line treatment. SSRI, venlafaxine, and mirtazapine were the 1st-line AD. In case of a partial or no response to initial strategy, adding another AD was recommended. For psychotic major depression, combination of an AD and an atypical antipsychotic (AAP) was the treatment of choice. Among AAPs, quetiapine, rispendone, olanzapine were preferred. For non-responder to initial strategy, the next step was adding or changing AD before changing AAP. For women with premenstrual dysphoric syndrome or postpartum depression without psychotic features, AD monotherapty was a preferred strategy while for psychotic postpartum depression, combination of AD and AAP was recommended. Experts recommended various ADs according to adverse effect. Conclusion : These results suggest that the medication strategies for depressive disorder are rapidly changing and reflect the recent studies and clinical experiences.
CHARACTERIZATION OF A NOVEL DIVERGENT CALMODULIN ISOFORM FROM SOYBEAN
Lee, Sang-Hyoung,Kim, Jong-Cheol,Lee, Mal-Soon,Cheong, Yong-Hwa,Yoon, Hae-Won,Lim, Chae-Oh,Hong, Jong-Chan,Bahk, Jeong-Dong,Lee, Sang-Yeol,Hwang, In-Hwan,Cho, Moo-Je Plant Molecular Biology & Biotechnology Research C 1993 Plant molecular biology and biotechnology research Vol.1993 No.
DIFFERENTIAL ACTIVATION OF CALMODULIN-DEPENDENT ENZYMES BY SOYBEAN CALMODULIN ISOFORMS
Lee, Sang-Hyoung,Kim, Jong-Cheol,Lee, Mal-Soon,Heo, Won-Do,Seo, Hae-Young,Yoon, Hae-Won,Hong, Jong-Chan,Lee, Sang-Yeol,Bahk, Jeong-Dong,Hwang, In-Hwan,Cho, Moo-Je Plant Molecular Biology & Biotechnology Research C 1994 Plant molecular biology and biotechnology research Vol.1994 No.
PURIFICATION AND CHARACTERIZATION OF CHITINASE ISOFORMS FROM S.marcescens ATCC27117
Gal, Sang-Wan,Kim, Cha-Young,Bae, Chang-Gyu,Kang, Chang-Ho,Bahk, Jeong-Dong,Lee, Sang-Yeol,Cho, Moo-Je Gyeongsang National University Chinju, Korea 1992 Plant molecular biology and biotechnology research Vol.1992 No.
Yang, Jaewon,Bahk, Won-Myong,Cho, Hyun-Sang,Jeon, Yang-Whan,Jon, Duk-In,Jung, Hee-Yeon,Kim, Chan-Hyung,Kim, Hee-Cheol,Kim, Yong-Ku,Kim, Young-Hoon,Kwon, Jun-Soo,Lee, Sang-Yeol,Lee, Seung-Hwan,Yi, Jung Lippincott Williams Wilkins, Inc. 2010 Clinical neuropharmacology Vol.33 No.4
OBJECTIVES:: The objective of this study was to evaluate the efficacy and tolerability of blonanserin for the treatment of Korean patients with schizophrenia using a double-blind risperidone-compared design. METHODS:: Patients aged 18 to 65 years with schizophrenia were randomly assigned to blonanserin or risperidone treatment for 8 weeks. The efficacy was assessed using the mean change in Positive and Negative Syndrome Scale score total scores from baseline to week 8. Safety assessments included monitoring of vital signs, a physical examination, laboratory tests, and adverse events. RESULTS:: Of 206 randomly enrolled patients, 103 receiving blonanserin and 103 receiving risperidone were included in the analysis. In this study, noninferiority between blonanserin and risperidone was demonstrated. The mean change in the Positive and Negative Syndrome Scale total score at the final evaluation time point was −23.48 ± 19.73 for the blonanserin group and −25.40 ± 18.38 for the risperidone group. Adverse events, which occurred less frequently in the blonanserin than in the risperidone group, included dysarthria (P = 0.0288), dizziness (P = 0.0139), increased alanine aminotransferase and aspartate aminotransferase (P = 0.0095 and P = 0.0032, respectively), and increased level blood prolactin (P = 0.0012). On the other hand, the adverse events that occurred more frequently in the blonanserin than in the risperidone group was hand tremor (P = 0.0006). CONCLUSIONS:: Blonanserin was effective in the treatment of Korean patients with schizophrenia compared with risperidone and was more tolerable with a better safety profile, particularly with respect to prolactin elevation. These findings suggest that blonanserin is useful in the treatment of schizophrenia.
Ha, Mi-Sook,Gal, Sang-Wan,Kim, Cha-Young,Koo, Ja-Chun,Bae, Chang-Gyu,Choi, Young-Ju,Chun, Hyun-Jin,Lee, Sang-Yeol,Bahk, Jeong-Dong,Cho, Moo-Je Plant Molecular Biology & Biotechnology Research C 1994 Plant molecular biology and biotechnology research Vol.1994 No.
To investigate the regulatory mechanisms and enzymatic characteristics of chitinolytic activity in Serattia marcescens k, two genes encoding 52kD 2kD chitinase were isolated from a cosmid library prepared from S. marcescens genomic DNA and expressed in Escherichia coli. Chitinase activity of the insert bearing the cloned was detected on chitin medium and confirmed by unbinding profiles of the fluorescent chitin binding reagent (Calcofluor White M2R) on SDS-PAGE gel containing glycol chitin. The chitinases were purified chitin affinity column chromatography from culture supernatant of E. coli transformants. Nucleotide and peptide sequences of the two chitinase were determined. The 52kD chitinase gene was consisted of 2563bp of open reading frame encoding 521 amino acids. The 52kD chitinase showed 97.3% sequence similarity to 52kD chitinase reported by Mark et al (1989). The leader sequence of the enzyme was not detected in the N-terminal region of the purified 52kD chitinase. The 21kD chitinase gene was located to 1504 bp downstream from the termination codon of 52kD and it had 666bp of open reading frame which encoded 222 amino acids. The N-terminal amino acid sequence of the 25kD chitinase determined from purified protein was STRKAVIGYYFIPTNQINNY and that of 21kD isozyme was HGYVESPASRPASRAYQCKLQLNTQXGXVQYEPQ. The 52kD chitinase cleaved chitohexaose to predominantly N,N'-diacetylchitobiose and a trace amount of N-acetylglucosamine. However 21kD isozyme produced only N,N'-diacetylchitobiose.order. The optimum pH temperature of 52kD chitinase were 5.0-6.0 and 50℃, those of 2kD chitinase were pH 6.0, 65℃, respectively.